BETブロモドメインの選択的阻害
Panagis Filippakopoulos1, Jun Qi, Sarah Picaud
1Department of Clinical Medicine, Structural Genomics Consortium, University of Oxford, Old Road Campus, Roosevelt Drive, Oxford OX3 7DQ, UK.
Nature
|September 28, 2010
まとめ
研究者たちは,ブロモドメインと呼ばれるエピジェネティックリーダータンパク質を阻害する小さな分子であるJQ1を開発しました. この分子は,BRD4タンパク質を標的とし,新しい治療戦略を提供することで,特定のがんの治療に希望を示しています.
科学分野:
- エピジェネティクス エピジェネティクス
- 化学生物学 化学生物学とは
- 癌生物学 癌生物学について
背景:
- エピジェネティックタンパク質は薬剤発見の重要なターゲットですが,ヒストン結合モジュール (ブロモドメイン) の阻害剤は不足しています.
- エピジェネティック"ライター"や"消し消し器"は成功しているが",読者"はほとんどターゲットになっていない.
研究 の 目的:
- ブロモドメインを標的とする小分子阻害剤の特定と特徴付け,これは表遺伝子読者タンパク質の一種である.
- 癌におけるブロモドメイン媒介タンパク質-タンパク質相互作用を阻害する治療の可能性を調査する.
主な方法:
- アセチルライシン結合モチーフを標的とした,細胞に浸透する小分子JQ1の開発.
- JQ1のブロモドメインとエクストラターミナル (BET) 家族 BRD4.4 との共結晶構造の決定
- 癌細胞系および患者由来の異種移植モデルにおけるJQ1のインビトロおよびインビボ試験.
主要な成果:
- JQ1は,ヒトブロモドメインのサブセット,特にBRD4.4に対して高い効能と特異性を示しました.
- 同結晶構造は,JQ1がBRD4のアセチルライシン腔に補完的に結合することを明らかにした.
- JQ1治療は,BRD4依存がんの状分化と抗増殖効果をもたらした.
結論:
- JQ1は,表遺伝子読者タンパク質の相互作用をターゲットにするための概念証明を表しています.
- この発見は,ブロモドメインを標的とする化学探査機の開発のための多用途の化学的支架を確立しています.
- BRD4をJQ1で標的にすることは,特定の治癒不可能な状がんの治療の可能性を示しています.
関連する概念動画
Eukaryotic Transcription Inhibitors
Certain biochemical processes, such as embryonic development and cell growth regulation, depend on the repression of specific genes. DNA binding proteins known as eukaryotic transcription inhibitors regulate the repression of gene expression in eukaryotes. The presence of these inhibitors at the required location and time in the cell is triggered by the presence of hormones and additional signals from other cells.
Eukaryotic transcription inhibitors usually contain two distinct domains, a DNA...
Eukaryotic transcription inhibitors usually contain two distinct domains, a DNA...
Dose-Response Relationship: Selectivity and Specificity
Drugs exert their therapeutic effects by interacting with receptors, enzymes, or ion channels that are present throughout the human body. The strength and duration of the interaction between a drug and its target receptor are characterized by the selectivity and specificity of the drug. Selectivity refers to a drug's strong preference for its intended target over other targets. For instance, isoprenaline, a non-selective β-adrenergic agonist, interacts with both β1- and β2-adrenergic receptors...
Inhibition of Cdk Activity
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Inhibition of CDK Activity
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Inhibitors of Bacterial DNA Synthesis
Bacterial pathogens depend on precise and efficient DNA replication to sustain infection. Two type II topoisomerases—DNA gyrase and topoisomerase IV—are critical to this process, as they resolve DNA supercoiling and unlink chromosomes during replication. Fluoroquinolones, synthetic derivatives of quinolones, exploit this mechanism by stabilizing the transient DNA–enzyme cleavage complex, preventing strand religation, and causing lethal double-strand breaks. These antibiotics are selectively...
Enzyme Inhibition
Inhibitors are molecules that reduce enzyme activity by binding to the enzyme. In a normally functioning cell, enzymes are regulated by a variety of inhibitors. Drugs and other toxins can also inhibit enzymes. Some inhibitors bind to the enzyme’s active site, while others inhibit enzymatic activity by binding to other sites on the protein structure.


